MX350418B - Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central. - Google Patents
Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central.Info
- Publication number
- MX350418B MX350418B MX2014015938A MX2014015938A MX350418B MX 350418 B MX350418 B MX 350418B MX 2014015938 A MX2014015938 A MX 2014015938A MX 2014015938 A MX2014015938 A MX 2014015938A MX 350418 B MX350418 B MX 350418B
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- con
- treatment
- heterocyclyl
- further described
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención se refiere a un compuesto de la fórmula general (I) o un derivado fisiológicamente funciona, solvato o sal del mismo, (I) en donde A es un enlace, alquilo o alcoxi opcionalmente substituido con uno o más R" como se define aquí, *-N(R''')CO-, *-CON(R''')-, *-N(R''')CON(R''')-, -S- -SO-, *-N(R''')-, *-N(R''')CO-, *-CON(R''')-, -CO-, *-COO-, *-OOC-, *-SO2N(R''')-, -SO2, o *-N(R''')-SO2-, en donde R'" es como se define aquí y * especifica el punto de unión a X; X es arilo, cicloalquilo, aralquilo, heterociclilo, o heteroarilo, el cual puede estar substituido con uno o más Rx como se describe además aquí; L es un enlace o *-N(RN)CO-, *-CON(RN)-, *-N(RN)-,*-C=N(RN)-, *-N(RN)-alquilo-, *-alquil-N(RN)-, *-N(RN)CON(RN)-, *-CO-,*-SO2-, alquilo, *-alquil-O-alquilo-, *-NCO-CH=CH-, *-CH=CH-CONH-, *-SO2N(RN)-, *-N(RN)SO2-, o heterociclilo, en donde * especifica el punto de unión a X; Y es H, alquilo, arilo, aralquilo, cicloalquilo, heterociclilo o heteroarilo, el cual puede estar substituido con uno o más Ry como se describe además aquí; y R y RN son además como se describe aquí, así como su uso como un medicamento, una composición farmacéutica que los comprende, un método para el tratamiento o prevención de una condición médica implicando su administración, y el uso del mismo en la elaboración de un medicamento para el tratamiento o prevención de una condición médica, particularmente trastornos inflamatorios autoinmunes, trastornos del sistema nervioso central, trastornos del dormir, o enfermedades proliferativas incluyendo cáncer. La invención además se refiere a un procedimiento específico para la preparación de dichos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015938A MX2014015938A (es) | 2015-07-21 |
| MX350418B true MX350418B (es) | 2017-09-06 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015938A MX350418B (es) | 2012-06-27 | 2013-06-27 | Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (es) |
| EP (1) | EP2867237A1 (es) |
| JP (2) | JP6272846B2 (es) |
| KR (1) | KR102155559B1 (es) |
| CN (1) | CN104540831B (es) |
| AU (2) | AU2013283318B2 (es) |
| BR (1) | BR112014032581A8 (es) |
| CA (1) | CA2877589C (es) |
| EA (1) | EA029718B1 (es) |
| HK (1) | HK1204474A1 (es) |
| IL (1) | IL236463A0 (es) |
| IN (1) | IN2014MN02562A (es) |
| MX (1) | MX350418B (es) |
| MY (1) | MY167785A (es) |
| NZ (1) | NZ702618A (es) |
| SG (1) | SG11201408617PA (es) |
| UA (1) | UA116541C2 (es) |
| WO (1) | WO2014001464A1 (es) |
| ZA (1) | ZA201409194B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116541C2 (uk) * | 2012-06-27 | 2018-04-10 | 4Ск Діскавері Гмбх | Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс |
| CN106661027B (zh) | 2014-03-20 | 2019-12-24 | 卡佩拉医疗公司 | 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症 |
| AU2015231202B9 (en) | 2014-03-20 | 2019-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
| CN107108581B (zh) | 2014-08-21 | 2020-06-23 | 百时美施贵宝公司 | 作为强效rock抑制剂的回接苯甲酰胺衍生物 |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| CR20200045A (es) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472) |
| AU2018355487B2 (en) | 2017-10-27 | 2023-09-21 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 |
| AU2019339186A1 (en) | 2018-09-13 | 2021-03-25 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | Raqualia Pharma Inc | METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| EP1957078B1 (en) | 2005-12-02 | 2013-08-28 | Bayer HealthCare, LLC | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| IN2012DN03312A (es) * | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
| UA116541C2 (uk) * | 2012-06-27 | 2018-04-10 | 4Ск Діскавері Гмбх | Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс |
-
2013
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko active IP Right Grant
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/xx unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1204474A1 (en) | 2015-11-20 |
| MY167785A (en) | 2018-09-25 |
| US20150158878A1 (en) | 2015-06-11 |
| AU2013283318A1 (en) | 2015-01-22 |
| EA029718B1 (ru) | 2018-05-31 |
| SG11201408617PA (en) | 2015-01-29 |
| AU2013283318B2 (en) | 2017-11-23 |
| ZA201409194B (en) | 2017-08-30 |
| WO2014001464A1 (en) | 2014-01-03 |
| EA201500050A1 (ru) | 2015-09-30 |
| CN104540831B (zh) | 2017-11-07 |
| CN104540831A (zh) | 2015-04-22 |
| IN2014MN02562A (es) | 2015-07-24 |
| EP2867237A1 (en) | 2015-05-06 |
| CA2877589C (en) | 2019-11-26 |
| AU2018201275A1 (en) | 2018-03-15 |
| CA2877589A1 (en) | 2014-01-03 |
| JP2018076360A (ja) | 2018-05-17 |
| JP2015525742A (ja) | 2015-09-07 |
| MX2014015938A (es) | 2015-07-21 |
| UA116541C2 (uk) | 2018-04-10 |
| BR112014032581A8 (pt) | 2018-08-14 |
| IL236463A0 (en) | 2015-02-26 |
| JP6272846B2 (ja) | 2018-01-31 |
| KR20150037877A (ko) | 2015-04-08 |
| BR112014032581A2 (pt) | 2017-06-27 |
| NZ702618A (en) | 2016-12-23 |
| KR102155559B1 (ko) | 2020-09-15 |
| US9580438B2 (en) | 2017-02-28 |
| US20170240556A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350418B (es) | Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central. | |
| EP2581376A4 (en) | MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| IN2014MN02106A (es) | ||
| IN2014MN01577A (es) | ||
| UA117122C2 (uk) | Хінолонові похідні | |
| MX2010008638A (es) | Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| IN2013DN02555A (es) | ||
| WO2014001215A3 (en) | 3-o-heteroaryl-ingenol | |
| MX355050B (es) | Derivados de quinolina antibacterianos. | |
| IN2015MN00045A (es) | ||
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MX2010013978A (es) | Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas. | |
| PH12015501056A1 (en) | 2-pyridone compound | |
| IN2014MN02433A (es) | ||
| MX2014013055A (es) | Derivados de quinolina antibacterianos. | |
| WO2014106826A3 (en) | Anthracycline analogue and uses thereof | |
| NZ700507A (en) | Pyrimidine derivatives for the treatment of bacterial diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |